Cabozantinib plus docetaxel and prednisone in metastatic castration-resistant prostate cancer

OBJECTIVE: To evaluate the safety and efficacy of cabozantinib combined with docetaxel. PATIENTS AND METHODS: This was a phase 1/2 multicentre study in patients with metastatic castration-resistant prostate cancer (mCRPC). Docetaxel (75 mg/m(2) every 3 weeks with daily prednisone 10 mg) was combined...

詳細記述

保存先:
書誌詳細
出版年:BJU Int
主要な著者: Madan, Ravi A., Karzai, Fatima H., Harthy, Munjid Al, Petrylak, Daniel P., Kim, Joseph W., Arlen, Philip M., Rosner, Inger, Theoret, Marc R., Cordes, Lisa, Bilusic, Marijo, Peer, Cody J., Dawson, Nancy A., Couvillon, Anna, Hankin, Amy, Williams, Moniquea, Chun, Guin, Owens, Helen, Marte, Jennifer L., Lee, Min-Jung, Tomita, Yusuke, Yuno, Akira, Trepel, Jane B., Lee, Sunmin, Steinberg, Seth M., Gulley, James L., Figg, William D., Dahut, William L.
フォーマット: Artigo
言語:Inglês
出版事項: 2020
主題:
Article
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC8265825/
https://ncbi.nlm.nih.gov/pubmed/32969563
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bju.15227
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料